{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:44:18Z","timestamp":1781261058468,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pcd.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:08:41Z","timestamp":1774861721000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9648-6266","authenticated-orcid":false,"given":"Navami","family":"K.S.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa Satyanarayan","family":"Basutkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2026.03.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.pcd.2026.03.008_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pcd.2026.03.008_bib3","article-title":"Evidence-based practice in prescribing SGLT2i and GLP-1 RA across ethnic and racial groups: a systematic review and meta-analysis of observational studies","author":"Ananthesh","year":"2025","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"10.1016\/j.pcd.2026.03.008_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2818","article-title":"Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis","volume":"33","author":"Min","year":"2017","journal-title":"Diabetes Metab. Res Rev."},{"key":"10.1016\/j.pcd.2026.03.008_bib5","unstructured":"RevMan 5.4_user_guide n.d."},{"key":"10.1016\/j.pcd.2026.03.008_bib6","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.pcd.2026.03.008_bib7","unstructured":"GRADE Handbook. n.d."},{"key":"10.1016\/j.pcd.2026.03.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.08.001","article-title":"Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study","volume":"47","author":"Liu","year":"2021","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.pcd.2026.03.008_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-017-0255-8","article-title":"A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin UMIN000015033 UMIN","volume":"9","author":"Nomoto","year":"2017","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.pcd.2026.03.008_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21486-9","article-title":"Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin","volume":"12","author":"Zeng","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pcd.2026.03.008_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s40842-022-00142-1","article-title":"Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial","volume":"8","author":"Mohammad zadeh Gharabaghi","year":"2022","journal-title":"Clin. Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2026.03.008_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4093\/dmj.2021.0319","article-title":"Comparison of serum ketone levels and cardiometabolic efficacy of dapagliflozin versus sitagliptin among insulin-treated chinese patients with type 2 diabetes mellitus","volume":"46","author":"Lee","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.pcd.2026.03.008_bib13","doi-asserted-by":"crossref","DOI":"10.47583\/ijpsrr.2024.v84i03.025","article-title":"Efficacy and safety of empagliflozin versus linagliptin as add on therapy to insulin in patients of chronic kidney disease and type 2 diabetes mellitus: a randomised controlled trial","volume":"84","author":"Hameed","year":"2024","journal-title":"Int J. Pharm. Sci. Rev. Res"},{"key":"10.1016\/j.pcd.2026.03.008_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jdi.12588","article-title":"Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: an open-label, single-center, parallel, randomized control study","volume":"8","author":"Okajima","year":"2017","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.pcd.2026.03.008_bib15","article-title":"Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients","volume":"13","author":"Park","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pcd.2026.03.008_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.781379","article-title":"Comparison of adverse kidney outcomes with empagliflozin and linagliptin use in patients with type 2 diabetic patients in a real-world setting","volume":"12","author":"Lee","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.pcd.2026.03.008_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ehjcvp\/pvad086","article-title":"New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study","volume":"10","author":"Gao","year":"2024","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"key":"10.1016\/j.pcd.2026.03.008_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7326\/M22-2751","article-title":"Primary occurrence of cardiovascular events after adding sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists compared with dipeptidyl peptidase-4 inhibitors: a cohort study in veterans with diabetes","volume":"176","author":"Richardson","year":"2023","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.pcd.2026.03.008_bib19","unstructured":"Book Series C., Higgins J.P., Green S. Cochrane Handbook for Systematic Reviews of Interventions THE COCHRANE COLLABORATION \u00ae. n.d."},{"key":"10.1016\/j.pcd.2026.03.008_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.pcd.2026.03.008_bib21","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014"},{"key":"10.1016\/j.pcd.2026.03.008_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2026.03.008_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-016-0403-8","article-title":"The EMPA-REG outcome study: critical appraisal and potential clinical implications","volume":"15","author":"Perseghin","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.pcd.2026.03.008_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13300-017-0277-0","article-title":"Practical approach to initiating SGLT2 inhibitors in type 2 diabetes","volume":"8","author":"Gomez-Peralta","year":"2017","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.pcd.2026.03.008_bib25","first-page":"17","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"13","author":"Steiner","year":"2016","journal-title":"Z. Fur Gefass"},{"key":"10.1016\/j.pcd.2026.03.008_bib26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the american diabetes association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2026.03.008_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.pcd.2026.03.008_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155243","article-title":"SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study","volume":"137","author":"Sardu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.pcd.2026.03.008_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9733","key":"10.1016\/j.pcd.2026.03.008_bib30","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991826000690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991826000690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:25:31Z","timestamp":1779107131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991826000690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1751991826000690"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2026.03.008","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}